About Supernus Pharmaceuticals (NASDAQ:SUPN)
Supernus Pharmaceuticals, Inc., a specialty pharmaceutical company, focuses on the development and commercialization of products for the treatment of central nervous system diseases in the United States. It offers Oxtellar XR, an extended-release oxcarbazepine for use in the treatment of epilepsy; and Trokendi XR, an extended-release topiramate, which is used for the treatment of epilepsy. The company's product candidates comprise SPN-810, a molindone hydrochloride that is in Phase III clinical trial for the treatment of impulsive aggression in patients with attention deficit hyperactivity disorder (ADHD); and SPN-812, a viloxazine hydrochloride, which is in Phase III clinical trial that is used for the treatment of ADHD. It also develops SPN-809, a viloxazine hydrochloride, which is in Phase II ready clinical trial for the treatment of depression. The company markets its products through wholesalers and pharmaceutical distributors. Supernus Pharmaceuticals, Inc. was founded in 2005 and is based in Rockville, Maryland.
Industry, Sector and Symbol
Industry Pharmaceutical preparations
Sub-IndustryPharmaceuticals
SectorMedical
SymbolNASDAQ:SUPN
CUSIP86845910
Phone301-838-2500
Debt
Debt-to-Equity RatioN/A
Current Ratio1.86%
Quick Ratio1.72%
Price-To-Earnings
Trailing P/E Ratio38.53
Forward P/E Ratio26.24
P/E GrowthN/A
Sales & Book Value
Annual Sales$302.24 million
Price / Sales8.28
Cash Flow$1.4703 per share
Price / Cash33.02
Book Value$5.22 per share
Price / Book9.30
Profitability
EPS (Most Recent Fiscal Year)$1.26
Net Income$57.28 million
Net Margins18.95%
Return on Equity28.07%
Return on Assets18.12%
Miscellaneous
Employees422
Outstanding Shares51,540,000
Supernus Pharmaceuticals (NASDAQ:SUPN) Frequently Asked Questions
What is Supernus Pharmaceuticals' stock symbol?
Supernus Pharmaceuticals trades on the NASDAQ under the ticker symbol "SUPN."
How were Supernus Pharmaceuticals' earnings last quarter?
Supernus Pharmaceuticals (NASDAQ:SUPN) announced its earnings results on Tuesday, February, 27th. The specialty pharmaceutical company reported $0.44 earnings per share for the quarter, topping the Zacks' consensus estimate of $0.26 by $0.18. The specialty pharmaceutical company earned $88.44 million during the quarter, compared to the consensus estimate of $87.84 million. Supernus Pharmaceuticals had a net margin of 18.95% and a return on equity of 28.07%. View Supernus Pharmaceuticals' Earnings History.
When is Supernus Pharmaceuticals' next earnings date?
What price target have analysts set for SUPN?
10 analysts have issued 1-year target prices for Supernus Pharmaceuticals' stock. Their forecasts range from $41.00 to $66.00. On average, they expect Supernus Pharmaceuticals' stock price to reach $51.90 in the next year. View Analyst Ratings for Supernus Pharmaceuticals.
What are Wall Street analysts saying about Supernus Pharmaceuticals stock?
Here are some recent quotes from research analysts about Supernus Pharmaceuticals stock:
- 1. According to Zacks Investment Research, "Supernus Pharmaceuticals Inc. is a specialty pharmaceutical company focused on developing and commercializing products for the treatment of central nervous system diseases. It is developing several product candidates in neurology and psychiatry to address opportunities in epilepsy and attention deficit hyperactivity disorder. Supernus Pharmaceuticals Inc. is based in Rockville, Maryland. " (1/12/2018)
- 2. FBR & Co analysts commented, "We are initiating coverage of Supernus Pharmaceuticals (SUPN) with a Buy rating and a 12-month price target of $53 per share. We see strong revenue growth exceeding 25% per year for 2017–2019 with in-line drugs Trokendi XR (epilepsy/ migraine) and Oxtellar XR (epilepsy) driving growth. Starting in 2020, we expect contribution from late-stage pipeline drugs SPN-812, which is a non-stimulant ADHD drug, and SPN-810 for impulsive aggression. We model EPS at $1.05 in 2017, $1.70 in 2018, and $2.35 in 2019 including a full tax rate. Our 2017 EPS estimate compares unfavorably to 2016, which included a tax benefit of $40.8 million or ~$0.80 per share. Our price target averages our DCF valuation and a P/E-derived target, which is 35x 2018E EPS of $1.70 discounted to present at 10%. At current prices, the shares have corrected by ~18% from all-time highs after an update on pipeline drug SPN-810 raised risks on timing/approvability. We see this drop as an opportunity to establish positions." (10/19/2017)
- 3. Cantor Fitzgerald analysts commented, "Interim look at SPN-810 Phase 3 program leads to elimination of the low dose. SUPN announced that an interim analysis of the ongoing Phase 3 trials (CHIME 1 and CHIME 2) in impulsive aggression (IA) resulted in the decision to discontinue the low dose arm, 18mg daily, and randomization of future clinical trial subjects to receive either placebo or 36mg per day." (9/19/2017)
Who are some of Supernus Pharmaceuticals' key competitors?
Some companies that are related to Supernus Pharmaceuticals include United Therapeutics (UTHR), Hutchison China MediTech (HCM), Taro Pharmaceutical Industries (TARO), Loxo Oncology (LOXO), FibroGen (FGEN), Blueprint Medicines (BPMC), GW Pharmaceuticals (GWPH), Ligand Pharmaceuticals (LGND), Advanced Accelerator Application (AAAP), Array Biopharma (ARRY), Tesaro (TSRO), Clovis Oncology (CLVS), Amicus Therapeutics (FOLD), Emergent BioSolutions (EBS), Ultragenyx Pharmaceutical (RARE), Ascendis Pharma (ASND), Ironwood Pharmaceuticals (IRWD) and Evotec A.G. (EVTCY).
Who are Supernus Pharmaceuticals' key executives?
Supernus Pharmaceuticals' management team includes the folowing people:
- Mr. Jack A. Khattar, Founder, Pres, CEO, Sec. & Director (Age 57)
- Mr. Gregory S. Patrick, VP, CFO & Principal Accounting Officer (Age 67)
- Dr. Padmanabh P. Bhatt Ph.D., Chief Scientific Officer and Sr. VP of Intellectual Property (Age 61)
- Mr. Victor L. Vaughn, Sr. VP of Sales and Marketing (Age 60)
- Dr. Stefan K. F. Schwabe M.D., Ph.D., Chief Medical Officer and Exec. VP of R&D (Age 66)
Has Supernus Pharmaceuticals been receiving favorable news coverage?
News stories about SUPN stock have been trending somewhat positive on Saturday, according to Accern Sentiment. The research firm scores the sentiment of media coverage by monitoring more than twenty million blog and news sources in real-time. Accern ranks coverage of companies on a scale of negative one to one, with scores nearest to one being the most favorable. Supernus Pharmaceuticals earned a media sentiment score of 0.16 on Accern's scale. They also gave media headlines about the specialty pharmaceutical company an impact score of 47.44 out of 100, meaning that recent media coverage is somewhat unlikely to have an impact on the company's share price in the next few days.
How do I buy shares of Supernus Pharmaceuticals?
Shares of SUPN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Supernus Pharmaceuticals' stock price today?
One share of SUPN stock can currently be purchased for approximately $48.55.
How big of a company is Supernus Pharmaceuticals?
Supernus Pharmaceuticals has a market capitalization of $2.48 billion and generates $302.24 million in revenue each year. The specialty pharmaceutical company earns $57.28 million in net income (profit) each year or $1.26 on an earnings per share basis. Supernus Pharmaceuticals employs 422 workers across the globe.
How can I contact Supernus Pharmaceuticals?
Supernus Pharmaceuticals' mailing address is 1550 E GUDE DR, ROCKVILLE MD, 20850. The specialty pharmaceutical company can be reached via phone at 301-838-2500 or via email at [email protected]
MarketBeat Community Rating for Supernus Pharmaceuticals (SUPN)
MarketBeat's community ratings are surveys of what our community members think about Supernus Pharmaceuticals and other stocks. Vote "Outperform" if you believe SUPN will outperform the S&P 500 over the long term. Vote "Underperform" if you believe SUPN will underperform the S&P 500 over the long term. You may vote once every thirty days.
Supernus Pharmaceuticals (NASDAQ:SUPN) Price Target and Consensus Rating
(How are Consensus Ratings Calculated?) MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
10 Wall Street analysts have issued ratings and price targets for Supernus Pharmaceuticals in the last 12 months. Their average twelve-month price target is $51.90, suggesting that the stock has a possible upside of 6.90%. The high price target for SUPN is $66.00 and the low price target for SUPN is $41.00. There are currently 1 hold rating and 9 buy ratings for the stock, resulting in a consensus rating of "Buy."
| Today | 30 Days Ago | 90 Days Ago | 180 Days Ago |
| Consensus Rating: | Buy | Buy | Buy | Buy |
| Consensus Rating Score: | 2.90 | 2.90 | 2.89 | 2.57 |
| Ratings Breakdown: | 0 Sell Rating(s)
1 Hold Rating(s)
9 Buy Rating(s)
0 Strong Buy Rating(s) | 0 Sell Rating(s)
1 Hold Rating(s)
9 Buy Rating(s)
0 Strong Buy Rating(s) | 0 Sell Rating(s)
1 Hold Rating(s)
8 Buy Rating(s)
0 Strong Buy Rating(s) | 0 Sell Rating(s)
3 Hold Rating(s)
4 Buy Rating(s)
0 Strong Buy Rating(s) |
| Consensus Price Target: | $51.90 | $51.90 | $50.3333 | $48.2857 |
| Price Target Upside: | 6.90% upside | 32.91% upside | 8.24% upside | 16.63% upside |
Supernus Pharmaceuticals (NASDAQ:SUPN) Consensus Price Target History
Supernus Pharmaceuticals (NASDAQ:SUPN) Analyst Ratings History
Show:
(Data available from 4/21/2016 forward)
Supernus Pharmaceuticals (NASDAQ:SUPN) Dividend History by Quarter
| Announced | Period | Amount | Yield | Ex-Dividend Date | Record Date | Payable Date |
|---|
(Data available from 1/1/2013 forward)
Supernus Pharmaceuticals (NASDAQ SUPN) Insider Trading and Institutional Ownership History
Insider Ownership Percentage: 6.70%
Institutional Ownership Percentage: 97.35%
Supernus Pharmaceuticals (NASDAQ SUPN) Insider Trading History
| Transaction Date | Insider Name | Title | Buy/Sell | Number of Shares | Average Share Price | Total Transaction | Shares Held After Transaction | Details |
|---|
| 4/19/2018 | Victor Vaughn | VP | Sell | 17,850 | $47.93 | $855,550.50 | 15,594 |  |
| 4/5/2018 | Victor Vaughn | VP | Sell | 60,000 | $45.33 | $2,719,800.00 | 24,344 | |
| 1/22/2018 | Padmanabh P Bhatt | VP | Sell | 20,000 | $48.04 | $960,800.00 | 32,500 | |
| 1/17/2018 | Padmanabh P Bhatt | VP | Sell | 20,000 | $44.98 | $899,600.00 | 32,500 | |
| 1/12/2018 | Victor Vaughn | VP | Sell | 5,750 | $45.03 | $258,922.50 | 15,094 | |
| 1/11/2018 | Gregory S. Patrick | CFO | Sell | 50,000 | $43.56 | $2,178,000.00 | | |
| 1/9/2018 | Victor Vaughn | VP | Sell | 15,000 | $42.04 | $630,600.00 | 24,344 | |
| 1/2/2018 | Victor Vaughn | VP | Sell | 55,000 | $40.11 | $2,206,050.00 | | |
| 9/8/2017 | Gregory S. Patrick | CFO | Sell | 50,000 | $47.60 | $2,380,000.00 | | |
| 9/8/2017 | Padmanabh P Bhatt | SVP | Sell | 5,000 | $49.86 | $249,300.00 | 12,500 | |
| 9/7/2017 | Stefan K.F. Schwabe | Insider | Sell | 95,000 | $46.59 | $4,426,050.00 | | |
| 8/16/2017 | Padmanabh P Bhatt | VP | Sell | 3,709 | $45.23 | $167,758.07 | 17,500 | |
| 7/12/2017 | Padmanabh P Bhatt | VP | Sell | 3,735 | $44.90 | $167,701.50 | 21,209 | |
| 6/23/2017 | Padmanabh P Bhatt | VP | Sell | 2,556 | $44.90 | $114,764.40 | 24,944 | |
| 6/2/2017 | Padmanabh P Bhatt | VP | Sell | 10,000 | $39.86 | $398,600.00 | 27,500 | |
| 5/26/2017 | Padmanabh P Bhatt | VP | Sell | 2,500 | $35.90 | $89,750.00 | 37,500 | |
| 5/25/2017 | Padmanabh P Bhatt | VP | Sell | 5,500 | $34.90 | $191,950.00 | 43,887 | |
| 4/24/2017 | Gregory S Patrick | CFO | Sell | 54,000 | $32.37 | $1,747,980.00 | 54,221 | |
| 4/24/2017 | Padmanabh P Bhatt | VP | Sell | 11,806 | $32.59 | $384,757.54 | 45,500 | |
| 9/16/2016 | Gregory S Patrick | CFO | Sell | 2,000 | $25.00 | $50,000.00 | 3,616 | |
| 7/14/2016 | Gregory S. Patrick | CFO | Sell | 3,395 | $22.00 | $74,690.00 | | |
| 4/11/2016 | Padmanabh P Bhatt | VP | Sell | 30,762 | $16.49 | $507,265.38 | 57,306 | |
| 12/9/2015 | Padmanabh P. Bhatt | VP | Sell | 14,238 | $14.90 | $212,146.20 | 88,068 | |
| 12/8/2015 | M James Barrett | Director | Sell | 212,970 | $14.56 | $3,100,843.20 | 115,355 | |
| 11/25/2015 | M James Barrett | Director | Sell | 16,179 | $16.35 | $264,526.65 | 73,929 | |
| 11/18/2015 | M James Barrett | Director | Sell | 93,000 | $16.61 | $1,544,730.00 | 73,929 | |
| 11/16/2015 | M James Barrett | Director | Sell | 119,650 | $16.24 | $1,943,116.00 | 73,929 | |
| 11/4/2015 | Padmanabh P Bhatt | VP | Sell | 5,000 | $19.90 | $99,500.00 | 102,306 | |
| 7/16/2015 | Gregory S Patrick | CFO | Sell | 6,217 | $20.00 | $124,340.00 | | |
| 7/13/2015 | Stefan K.F. Schwabe | EVP | Sell | 1,950 | $19.23 | $37,498.50 | | |
| 6/17/2015 | M James Barrett | Director | Sell | 111,881 | $16.39 | $1,833,729.59 | | |
| 6/17/2015 | Scott D Sandell | Major Shareholder | Sell | 136,597 | $16.50 | $2,253,850.50 | | |
| 6/16/2015 | M James Barrett | Director | Sell | 55,105 | $16.85 | $928,519.25 | | |
| 6/16/2015 | Scott D Sandell | Major Shareholder | Sell | 95,437 | $16.92 | $1,614,794.04 | | |
| 6/12/2015 | Stefan K.F. Schwabe | EVP | Sell | 2,051 | $18.27 | $37,471.77 | | |
| 6/11/2015 | Stefan K.F. Schwabe | EVP | Sell | 3,631 | $16.39 | $59,512.09 | | |
| 3/24/2015 | Jones W Bryan | VP | Sell | 1,900 | $12.00 | $22,800.00 | | |
| 8/19/2013 | Padmanabh Bhatt | VP | Sell | 2,285 | $8.21 | $18,759.85 | 51,806 | |
| 3/22/2013 | Michael Bigham | Director | Buy | 35,000 | $5.41 | $189,350.00 | | |
| 3/21/2013 | John M Siebert | Director | Buy | 3,000 | $5.50 | $16,500.00 | | |
| 3/15/2013 | Jack A Khattar | CEO | Buy | 10,000 | $6.15 | $61,500.00 | | |
| 3/14/2013 | Gregory S Patrick | CFO | Buy | 5,000 | $6.95 | $34,750.00 | | |
| 12/4/2012 | John M Siebert | Director | Buy | 7,000 | $8.14 | $56,980.00 | | |
(Data available from 1/1/2013 forward)
Supernus Pharmaceuticals (NASDAQ SUPN) News Headlines
| Source: |
|
| Date | Headline |
|---|
 | Insider Selling: Supernus Pharmaceuticals (SUPN) VP Sells 17,850 Shares of Stock
www.americanbankingnews.com - April 20 at 7:22 PM |
 | Harry Boxer’s biotech-stock breakouts to watch
finance.yahoo.com - April 19 at 5:40 PM |
| Supernus Pharmaceuticals (SUPN) Upgraded to "Buy" by Zacks Investment Research
www.americanbankingnews.com - April 18 at 3:33 PM |
| Supernus Pharmaceuticals (SUPN) Downgraded by Piper Jaffray to Neutral
www.americanbankingnews.com - April 17 at 11:58 PM |
| Supernus Pharmaceuticals (SUPN) Rating Lowered to Hold at Zacks Investment Research
www.americanbankingnews.com - April 17 at 6:29 PM |
| Supernus Pharmaceuticals (SUPN) Rating Reiterated by Stifel Nicolaus
www.americanbankingnews.com - April 17 at 5:27 PM |
| BidaskClub Downgrades Supernus Pharmaceuticals (SUPN) to Buy
www.americanbankingnews.com - April 16 at 12:19 AM |
| Zacks: Brokerages Expect Supernus Pharmaceuticals (SUPN) Will Post Quarterly Sales of $87.82 Million
www.americanbankingnews.com - April 15 at 2:46 AM |
| Supernus Pharmaceuticals (SUPN) Stock Rating Reaffirmed by Cowen
www.americanbankingnews.com - April 13 at 6:39 PM |
| Zacks: Brokerages Expect Supernus Pharmaceuticals (SUPN) to Announce $0.33 EPS
www.americanbankingnews.com - April 13 at 5:17 PM |
 | Form 4 SUPERNUS PHARMACEUTICALS For: Apr 05 Filed by: Vaughn Victor
www.streetinsider.com - April 11 at 5:32 PM |
| Factors of Influence in 2018, Key Indicators and Opportunity within Harmonic, Supernus Pharmaceuticals, America First Multifamily Investors, Ballard Power, ServiceSource International, and Materialise NV — New Research Emphasizes Economic Growth
finance.yahoo.com - April 11 at 8:30 AM |
| Here’s What Drove Supernus Pharmaceuticals Stock in March 2018
finance.yahoo.com - April 9 at 5:23 PM |
| Victor Vaughn Sells 60,000 Shares of Supernus Pharmaceuticals (SUPN) Stock
www.americanbankingnews.com - April 9 at 1:17 PM |
 | Commit To Purchase Supernus Pharmaceuticals At $36, Earn 14.2% Annualized Using Options
www.nasdaq.com - April 6 at 5:42 PM |
| Piper Jaffray Analysts Give Supernus Pharmaceuticals (SUPN) a $41.00 Price Target
www.americanbankingnews.com - April 4 at 4:44 PM |
| Supernus Pharmaceuticals (SUPN) Given Average Rating of "Buy" by Analysts
www.americanbankingnews.com - April 4 at 1:47 PM |
| Supernus Pharmaceuticals (SUPN) Earns "Buy" Rating from B. Riley
www.americanbankingnews.com - April 1 at 10:23 AM |
| Edited Transcript of SUPN earnings conference call or presentation 28-Feb-18 2:00pm GMT
finance.yahoo.com - March 30 at 8:22 AM |
| Brokerages Anticipate Supernus Pharmaceuticals (SUPN) to Announce $0.33 EPS
www.americanbankingnews.com - March 27 at 7:20 PM |
| Supernus Pharmaceuticals (SUPN) Research Coverage Started at Berenberg Bank
www.americanbankingnews.com - March 25 at 9:48 PM |
| Supernus Pharmaceuticals Expected to Earn FY2018 Earnings of $1.84 Per Share (SUPN)
www.americanbankingnews.com - March 23 at 9:56 AM |
| Supernus Pharmaceuticals (SUPN) to Post Q1 2018 Earnings of $0.35 Per Share, SunTrust Banks Forecasts
www.americanbankingnews.com - March 22 at 8:12 AM |
| Supernus Pharmaceuticals (SUPN) Rating Increased to Strong-Buy at BidaskClub
www.americanbankingnews.com - March 21 at 10:36 PM |
 | Supernus Announces Pricing of $350 Million Private Offering of ... - GlobeNewswire (press release)
globenewswire.com - March 16 at 8:18 AM |
 | BRIEF-Supernus Announces Pricing Of $350 Mln Private Offering Of 0.625 Pct Convertible Senior Notes
www.reuters.com - March 15 at 6:13 PM |
| Supernus Announces Pricing of $350 Million Private Offering of 0.625% Convertible Senior Notes - Nasdaq
www.nasdaq.com - March 15 at 8:15 AM |
| Supernus Pharma (SUPN) Proposed Private Offering of $350 Million ... - StreetInsider.com
www.streetinsider.com - March 14 at 8:31 AM |
| Supernus Pharma (SUPN) Proposed Private Offering of $350 Million of Convertible Senior Notes
www.streetinsider.com - March 13 at 7:18 PM |
| Supernus Announces Proposed Private Offering of $350 Million of Convertible Senior Notes
finance.yahoo.com - March 13 at 7:18 PM |
| Supernus Pharmaceuticals (SUPN) Rating Increased to Buy at BidaskClub
www.americanbankingnews.com - March 10 at 11:00 PM |
| Supernus Pharmaceuticals Inc (SUPN) Given Average Rating of "Buy" by Brokerages
www.americanbankingnews.com - March 10 at 3:11 PM |
 | Supernus Pharmaceuticals inks deal for new, expanded headquarters - Washington Business Journal
www.bizjournals.com - March 8 at 8:22 AM |
| FY2018 Earnings Estimate for Supernus Pharmaceuticals Inc Issued By Cantor Fitzgerald (SUPN)
www.americanbankingnews.com - March 7 at 11:50 AM |
| Supernus to Present at the 2018 Cowen Health Care Conference - GlobeNewswire (press release)
globenewswire.com - March 7 at 8:16 AM |
| Supernus Pharmaceuticals inks deal for new, expanded headquarters
finance.yahoo.com - March 6 at 5:41 PM |
| Supernus to Present at the 2018 Cowen Health Care Conference
finance.yahoo.com - March 6 at 5:41 PM |
| Wells Fargo & Company MN Grows Position in Supernus Pharmaceuticals Inc (SUPN)
www.americanbankingnews.com - March 6 at 3:09 PM |
| Supernus Pharmaceuticals Inc (SUPN) Shares Bought by Swiss National Bank
www.americanbankingnews.com - March 6 at 3:06 PM |
| Supernus Pharmaceuticals Inc (SUPN) Shares Bought by OppenheimerFunds Inc.
www.americanbankingnews.com - March 6 at 11:36 AM |
| Ranger Investment Management L.P. Has $21.78 Million Stake in Supernus Pharmaceuticals Inc (SUPN)
www.americanbankingnews.com - March 5 at 3:42 PM |
| Supernus Pharmaceuticals Inc Forecasted to Post FY2018 Earnings of $1.77 Per Share (SUPN)
www.americanbankingnews.com - March 5 at 5:02 AM |
| Supernus Pharmaceuticals Inc (SUPN) Forecasted to Post Q1 2018 Earnings of $0.36 Per Share
www.americanbankingnews.com - March 5 at 1:28 AM |
| Q1 2018 EPS Estimates for Supernus Pharmaceuticals Inc (SUPN) Lifted by B. Riley
www.americanbankingnews.com - March 5 at 1:28 AM |
| Supernus Pharmaceuticals Inc (SUPN) Stake Decreased by White Pine Capital LLC
www.americanbankingnews.com - March 4 at 2:46 PM |
| Supernus Pharmaceuticals (SUPN) Upgraded to Buy at ValuEngine
www.americanbankingnews.com - March 4 at 9:52 AM |
| State of Wisconsin Investment Board Raises Position in Supernus Pharmaceuticals Inc (SUPN)
www.americanbankingnews.com - March 4 at 9:32 AM |
| Royce & Associates LP Sells 60,000 Shares of Supernus Pharmaceuticals Inc (SUPN)
www.americanbankingnews.com - March 3 at 9:12 AM |
| Validea Motley Fool Strategy Daily Upgrade Report - 3/3/2018 - Nasdaq
www.nasdaq.com - March 3 at 8:15 AM |
| Arizona State Retirement System Grows Holdings in Supernus Pharmaceuticals Inc (SUPN)
www.americanbankingnews.com - March 3 at 4:22 AM |
Supernus Pharmaceuticals (NASDAQ:SUPN) SEC Filings
This page is loading this company's SEC Filings. Please wait...
Supernus Pharmaceuticals (NASDAQ:SUPN) Income Statement, Balance Sheet and Cash Flow Statement
Supernus Pharmaceuticals (NASDAQ SUPN) Stock Chart for Saturday, April, 21, 2018
Loading chart…
